摘要
重组人内皮抑素(rhEndostatin)是人内皮抑素经过基因突变获得的新的蛋白质序列,是一种血管生成抑制剂类蛋白,具有抗肿瘤活性。实验对蛋白rhEndostatin产生菌E.coliBL21(DE3)的基本发酵条件进行了研究并用正交试验对培养基成分进行了优化,优化后的培养基组成为:蛋白胨1%,酵母粉0.5%,葡萄糖0.5%,NaCl 0.2%,Na2HPO4.12 H2O 1.5%,KH2PO40.2%,(NH4)2SO40.2%,MgSO4.7 H2O 0.02%,VB15 mg/L,VB21 mg/L,微量元素:CoCl2.6 H2O 5 mg/L,MnCl2.4 H2O,H3BO3,Na2MoO4.2 H2O,AlCl3.6 H2O,Ferric citrate均20 mg/L。优化后的培养基在发酵罐发酵,湿菌重达到45 g/L以上,目的蛋白产量达324 mg/L,为rhEndostatin的进一步研究开发打下了基础。
rhEndostatin exerts its anti tumor effect quence corresponds to specific motifs on endostatin by the virtue of inhibition of angiogenesis. Its amino acid semolecule. The basic fermentation conditions of rhEndostatin host strain E. coli BL21（DE3） were studied, and orthogonal design was applied to optimize the fermentation medium constituents. The optimal levels for the constituents were as follows： Tryptone 1%, yeast extract powder 0.5%,NaCl 0.2%,Na2HPO4·12H2O 1.5%,KH2PO4 0.2%,（NH4）2SO4 0.2%, Glucose 0.5%, MgSO4·7H2O 0.02%,VB1 5mg/L,VB2 1mg/L, trace elements： CoCl2 ·6H2O 5 mg/L, MnCl2 · 4H2O, Na2MoO4·H2O, AlCl3 · 6H2O, H3BO3, and ferric citrate 20mg/L. With the optimal medium, the wet cell weight of bacterium reached over 45 g/L in 16 liter fermentor, and the yield of rhEndostatin reached 324mg/L, which laid the foundation for the further development of rhEndostatin.
出处
《药物生物技术》
CAS
CSCD
2008年第6期469-472,共4页
Pharmaceutical Biotechnology
